WTA Begins Genetic Sex Testing at Cincinnati Open

Nobody announced it. Nobody held a press conference. The WTA just started swabbing cheeks in Cincinnati, and it took a reporter asking Jessica Pegula a direct question for the rest of us to find out.

Pegula — the top-ranked American in the draw, confirmed as such in her interview with Front Office Sports — told the outlet Wednesday that genetic sex testing had begun at the Cincinnati Open, with the main draw set to start Thursday. According to Front Office Sports, the WTA approved the policy in July, though primary documentation from the organization itself hasn't been publicly linked. As Field Level Media noted, the rollout had largely slipped under the press's radar before Pegula's comments surfaced it.

So: a major governance shift in women's professional sports, implemented quietly, confirmed by a player rather than a press release. That's not nothing.

The test itself is more specific than the phrase "genetic sex testing" implies. According to WDSM 710, players are being screened for the SRY gene — the gene on the Y chromosome that typically triggers male sex development — via cheek swab or blood draw. The WTA has acknowledged internally, per reporting cited by KRRO and KWSN, that this is a sensitive and complex matter and that the organization is committed to handling it carefully. The full scope of that commitment — what appeals look like, how disputes get resolved, what happens to a flagged player — has not been made public in any detail the sources available here can confirm.

Here's the thing nobody's saying out loud: the SRY test is not as clean as it sounds.

The SRY gene is real and its role in sex development is well-documented, but human biology does not read policy memos. A meaningful subset of people — individuals with Complete Androgen Insensitivity Syndrome, or CAIS — carry an SRY gene and a Y chromosome but develop female anatomy and physiology throughout their lives, including at puberty. They've competed in women's sports for generations, often without knowing their chromosomal makeup. Testing for SRY flags them. Whatever eligibility consequence follows, those women — who have lived, trained, and competed as women their entire lives — are not the demographic the policy is aimed at. If the WTA's framework doesn't have a clear, humane answer for that scenario, it has a problem that goes well beyond the politics of the moment.

The WTA isn't operating in a vacuum here. This generation of women's sports fans — the ones who came of age watching Serena build an empire, who streamed Coco Gauff's run at Roland Garros on a phone while doing homework, who are currently keeping the NWSL and WNBA socially alive through sheer posting volume — they've watched these leagues professionalize in real time. Women's sports have spent the last decade fighting to be taken seriously as a product, as a business, as a cultural force. The audiences who drove that growth care deeply about the integrity of the competition. They also care, often in equal measure, about whether the institutions they've invested in are treating athletes with basic dignity.

That's not a contradiction. It's actually the tightest version of the problem the WTA has to solve.

Because if you're trying to square competitive integrity with individual dignity, the mechanism you choose matters enormously — and "we ran a gene test and here's what we found" is not a complete policy. It's a data point. The question is what the WTA does with it, and on that front, the public record is almost entirely blank. There's no published appeals framework, no clear communication about how players were notified the testing was coming, and — critically — no transparency about whether the policy's edge cases have been thought through. What happens to a player whose result is ambiguous? What happens to one who disputes it? Sports Radio KWSN's reporting gestures at institutional sensitivity without filling in any of those blanks.

Governing bodies across sport are working through versions of this same problem. World Athletics moved to testosterone threshold policies. Swimming's FINA (now World Aquatics) went further with categorical rules on transgender athlete eligibility. The IOC punted into ambiguity with its 2021 framework. Tennis, sitting across ITF and WTA jurisdictions simultaneously, has always had a more complicated governance stack than it looks — and layering a new biological eligibility test on top of that without clear public documentation of the process is a choice that will eventually create friction somewhere.

Maybe it already has and we just don't know yet.

The quiet rollout is either a sign that things are going smoothly — players were briefed, tested, and moved on without incident — or a sign that the hard cases haven't surfaced publicly. The Cincinnati Open is ongoing. There's no indication yet of any challenge, appeal, or contested result. But the policy is live, it's going to follow the tour from Cincinnati to whatever comes next, and the moment it produces a visible consequence, every question that wasn't answered in July becomes urgent.

Women's tennis built something genuinely valuable over the past decade. The business case for women's sports is no longer a hard sell — it's a documented phenomenon. The WTA's eligibility policy is, at some level, an attempt to protect that investment. Whether the specific mechanism they chose actually does that, or whether it creates new vulnerabilities they haven't stress-tested yet, is a question a cheek swab alone can't answer.

Anyone who tells you this is simple is selling you a take, not the truth.

Jai Trivedi covers sports media and technology for Buzzrag.